Product Description: Rolinsatamab is a potent dual IL-4 and IL-13 inhibitor as a fully humanized bispecific monoclonal antibody. Rolinsatamab chimeric antigen receptor sequence T cell. Rolinsatamab can be used in research of immune disease[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Ray EL, et, al. Protease switch for dual targets chimeric antigen receptor t cell therapy. WO2021087245.